Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Pfizer logo
PfizerPFE
$2.69B-9.4%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.09M-122%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$19.05M-8.5%
Nuvation Bio logo
Nuvation BioNUVB
$5.4M+110%
Immunome logo
ImmunomeIMNM
-$53.84M-29.3%

Segments

By segment

See full
Clinical Development-$6.05M-13.5%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s net income?
Nuvectis Pharma, Inc. (NVCT) reported net income of -$6.05M in Q1 2026.
How has Nuvectis Pharma, Inc.'s net income changed year-over-year?
Nuvectis Pharma, Inc.'s net income decreased by 13.5% year-over-year, from -$5.33M to -$6.05M.
What is the long-term trend for Nuvectis Pharma, Inc.'s net income?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s net income has grown at a 19.7% compound annual growth rate (CAGR), from -$12.89M to -$26.44M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.